RxDoctor Payments Data

Scott Bergeaux, MD

Family Medicine · Kaplan, LANPI 1568586014

Payments from drug & device makers

$305in general payments, 2019–2025

Across 16 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$99
  • Sumitomo Pharma America, Inc.$47
  • Getinge USA Sales, LLC$38
  • Lilly USA, LLC$34
  • Kowa Pharmaceuticals America, Inc.$26
  • Ironwood Pharmaceuticals, Inc$24
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$305 in reported general payments places this provider in the 35th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$172,284
Medicare patients
481
Services billed
1,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide201$197,684
EliquisApixaban218$142,781
OzempicSemaglutide83$88,527
MyrbetriqMirabegron168$75,592
JanuviaSitagliptin Phosphate74$61,769
MounjaroTirzepatide45$56,917
LinzessLinaclotide93$54,885
FarxigaDapagliflozin Propanediol75$49,087
JardianceEmpagliflozin57$44,621
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$29,567
XareltoRivaroxaban53$25,966
TradjentaLinagliptin42$24,732
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$18,584
EntrestoSacubitril/Valsartan37$17,529
Combivent RespimatIpratropium/Albuterol Sulfate35$17,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$34$254,601246 claims
PfizerEliquis, Premarin$22$145,455244 claims
AbbVieLinzess, Namzaric$99$61,421104 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$15$45,47394 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Kaplan

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →